NCT06652633Phase 3Recruiting

Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Study sponsor: Lakefront Biotherapeutics NV · LKFT

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2039-07Estimated

Enrollment · participants546Estimated

Source updated2026-07-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Hematological Malignancies

Treatments or interventions studied

Not recorded

Primary outcomes · main study measures

Read the study measures

measure: Percentage of participants with targeted adverse events (AEs); timeFrame: From infusion up to 15 years; measure: Percentage of participants with detectable CAR transgene levels in peripheral blood; timeFrame: From infusion up to 15 years; measure: Percentage of participants with serious AEs (SAEs) considered related to the Galapagos CAR T-cell therapy; timeFrame: From infusion up to 15 years; measure: Percentage of participants with at least 1% of T-cells in the blood sample or positive new malignancies; timeFrame: From infusion up to 15 years; measure: Percentage of participants with detectable replication-competent lentivirus (RCL) in peripheral blood; timeFrame: From infusion up to 15 years; measure: Percentage of participants who died with causes; timeFrame: From infusion up to 15 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history